AMNEAL PHARMACEUTICALS INC CLASS A (AMRX)
Health Care · Generic pharmaceuticals and specialty injectable manufacturing · NASDAQ
Global biopharmaceutical company manufacturing and distributing generic medicines, specialty pharmaceuticals, and injectable products with a growing biosimilar platform.
What AMNEAL PHARMACEUTICALS INC CLASS A does
Amneal Pharmaceuticals is a diversified biopharmaceutical company that develops, manufactures, markets, and distributes a portfolio of essential medicines across three segments: Affordable Medicines (generic drugs, injectables, and biosimilars), Specialty (branded pharmaceuticals for CNS and endocrine disorders), and AvKARE (pharmaceutical distribution for U.S. federal agencies, retail, and institutional markets). The company operates manufacturing and distribution facilities principally in the United States, India, and Ireland, and has strategic collaborations for injectable manufacturing and weight-loss medicine development.
Themes: ["Generic pharmaceuticals / affordable medicines"]
Fundamentals
- Price$17.02 as of 2026-07-09 close
- Market cap$5.4B as of 2026-07-10
- 1-year return+104.3% as of 2026-07-09 close
- P/E44.51 as of 2026-07-10
- Net margin+4.0% as of 2026-07-10
- Gross margin+38.7% as of 2026-07-10
- ROE-34.9% as of 2026-07-10
- Debt / equity136.58 as of 2026-07-10
- Revenue growth (YoY)+7.6% as of 2026-07-10
- Revenue CAGR (3y)+10.9% SEC XBRL
- Beta1.27 as of 2026-07-10
Key risks (from latest filing)
["High debt load ($2.6+ billion in long-term debt as of Q1 2026) with significant interest expense burden ($53.4 million in Q1 2026 alone), limiting financial flexibility and requiring profitable operations to service debt."]
Competitors & peers
- Teva Pharmaceutical Industries
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.